Sibutramine: current status as an anti-obesity drug and its future perspectives.

abstract：OBJECTIVE:Mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), is used to treat systemic lupus erythematosus (SLE). MMF and EC-MPS pharmacokinetics were examined to devise guidance for therapeutic drug monitoring (TDM) for SLE patients with normal ren...

journal_title：Expert opinion on pharmacotherapy

authors： Djabarouti S,Duffau P,Lazaro E,Chapouly C,Greib C,Viallard JF,Pellegrin JL,Saux MC,Breilh D

更新日期：2010-04-01 00:00:00

abstract：INTRODUCTION:Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Mutually, the symptoms of SBS-IF and the inconveniences and complications in relation to parenteral support may ...

journal_title：Expert opinion on pharmacotherapy

authors： Nørholk LM,Holst JJ,Jeppesen PB

更新日期：2012-02-01 00:00:00

abstract：INTRODUCTION:Phosphodiesterase type 5 inhibitors (PDE5-i) are used for the oral treatment of erectile dysfunction (ED). Since the launch of sildenafil more than 15 years ago, new molecules have become available. At present, in addition to tadalafil and vardenafil, there are three other drugs, udenafil, avanafil and mir...

journal_title：Expert opinion on pharmacotherapy

authors： Bruzziches R,Francomano D,Gareri P,Lenzi A,Aversa A

更新日期：2013-07-01 00:00:00

abstract：BACKGROUND:Prescription omega-3-acid ethyl esters (P-OM3) have been used as adjunctive therapy to statin drugs in patients with mixed hyperlipidemia. OBJECTIVE:To assess the effect of concomitant administration of 4 g P-OM3 on the steady-state pharmacokinetics of the maximum recommended daily dose of atorvastatin (80 ...

journal_title：Expert opinion on pharmacotherapy

authors： Di Spirito M,Morelli G,Doyle RT,Johnson J,McKenney J

更新日期：2008-12-01 00:00:00

abstract：BACKGROUND:Acute pulmonary embolism (PE) is a life-threatening condition that has been treated with anticoagulation for almost 50 years. OBJECTIVES:To review the current treatment options for PE and discuss recently published new features. METHODS:We reviewed literature involving the treatment strategies for venous t...

journal_title：Expert opinion on pharmacotherapy

authors： Blondon M,Bounameaux H,Righini M

更新日期：2009-05-01 00:00:00

abstract：:The incidence of nucleoside analogue-related lactic acidosis has been estimated in 0.57 - 8.5 cases/1000 person years of antiretroviral therapy. The onset of lactic acidosis is usually insidious and patients complain of nausea, vomiting, abdominal pain, fatigue and weight loss. When lactate levels are high enough, a c...

journal_title：Expert opinion on pharmacotherapy

authors： Falcó V,Crespo M,Ribera E

更新日期：2003-08-01 00:00:00

abstract：INTRODUCTION:Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of the central nervous system involving inflammation, chronic demyelination and axonal loss. MS affects more than 2 million people worldwide. AREAS COVERED:This article aims to summarize the findings from two pivotal 2-year, randomized, do...

journal_title：Expert opinion on pharmacotherapy

authors： Havrdova E,Hutchinson M,Kurukulasuriya NC,Raghupathi K,Sweetser MT,Dawson KT,Gold R

更新日期：2013-10-01 00:00:00

abstract：INTRODUCTION:actinic keratosis is a premalignant disease with a high incidence and is a strong predictor for the development of squamous cell carcinoma. Various treatment options have been established over recent years, including topical treatment with imiquimod, 5-fluorouracil, diclofenac or photodynamic therapy, cryo...

journal_title：Expert opinion on pharmacotherapy

authors： Quist SR,Gollnick HP

更新日期：2011-02-01 00:00:00

abstract：:Introduction: This clinical guidance looks at the specific concerns of delivery of medical treatment for people with epilepsy and intellectual disability (ID). People with ID have not been included in licensing drug trials of AEDs. However, this population has an over-representation of seizure comorbidity, treatment r...

journal_title：Expert opinion on pharmacotherapy

authors： Watkins L,O'Dwyer M,Kerr M,Scheepers M,Courtenay K,Shankar R

更新日期：2020-02-01 00:00:00

abstract：INTRODUCTION:Despite the availability of numerous anti-diabetes drugs and treatment guidelines, many patients with type 2 diabetes mellitus (T2DM) do not reach recommended targets for glycemic control. There remains an unmet need for effective and well-tolerated anti-diabetes agents that can be used as monotherapy or i...

journal_title：Expert opinion on pharmacotherapy

authors： Jahagirdar V,Barnett AH

更新日期：2014-11-01 00:00:00

abstract：INTRODUCTION:Psoriasis is a chronic, inflammatory disease afflicting 2% of the US population; it results in significant morbidity. The annual healthcare costs related to psoriasis are an estimated $11.3 billion and, with an expanding biologic market, an updated costs analysis is needed. AREAS COVERED:Current treatment...

journal_title：Expert opinion on pharmacotherapy

authors： Staidle JP,Dabade TS,Feldman SR

更新日期：2011-09-01 00:00:00

abstract：:Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption. Unlike other weight-reducing drugs it is minimally absorbed and has no effects in the CNS. Orlistat is indicated for patients with a body mass index (BMI) of at least 30 kg/m2 or 28 kg/m2 in th...

journal_title：Expert opinion on pharmacotherapy

authors： Ballinger A

更新日期：2000-05-01 00:00:00

abstract：:Parkinson's disease (PD) affects approximately 1% of individuals > 60 years. Of these PD patients approximately 40% suffer dementia in later life. Levodopa is commonly used in the treatment of PD. Experimental evidence suggests that the dopamine synthesised from levodopa may contribute to the further degeneration of d...

journal_title：Expert opinion on pharmacotherapy

authors： Doggrell SA

更新日期：2005-06-01 00:00:00

abstract：INTRODUCTION:Many patients with type 2 diabetes mellitus (T2DM) fail to achieve the desired A1c goal because the antidiabetic medications used do not correct the underlying pathophysiologic abnormalities and monotherapy is not sufficiently potent to reduce the A1c to the 6.5 - 7.0% range. Insulin resistance and islet (...

journal_title：Expert opinion on pharmacotherapy

authors： Triplitt C,Solis-Herrera C,Cersosimo E,Abdul-Ghani M,Defronzo RA

更新日期：2015-01-01 00:00:00

abstract：:The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention. Aspirin should be ...

journal_title：Expert opinion on pharmacotherapy

authors： Williams A,Hennekens CH

更新日期：2004-01-01 00:00:00

abstract：:Staphylococcus aureus is a bacterial pathogen responsible for a variety of serious infections and is a frequent cause of nosocomial disease. During the last 60 years, S. aureus has developed increasing in vitro resistance to virtually all antimicrobials. In contrast, vancomycin has maintained a high degree of activity...

journal_title：Expert opinion on pharmacotherapy

authors： Pope SD,Roecker AM

更新日期：2007-06-01 00:00:00

abstract：:Overweight, obesity and the metabolic syndrome occur in genetically susceptible individuals with environmental influences, and may be further compounded by other disorders of metabolism or pharmacological therapy that increase insulin resistance or promotes weight gain. Treatment of the metabolic syndrome should focus...

journal_title：Expert opinion on pharmacotherapy

authors： Stone NJ,Schmeltz LR

更新日期：2007-09-01 00:00:00

abstract：INTRODUCTION:The disturbing, foul-smelling discharge of bacterial vaginosis (BV) is a nuisance to women. Treatment possibilities for BV are limited and only achieve complete cure in 65 to 85% of cases. In most women, the condition relapses within weeks to months after treatment. AREAS COVERED:In search of new therapeu...

journal_title：Expert opinion on pharmacotherapy

authors： Donders GG,Zodzika J,Rezeberga D

更新日期：2014-04-01 00:00:00

abstract：INTRODUCTION:Patisiran and inotersen are two therapies approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, a rapidly progressive disease with a substantial clinical burden. This analysis indirectly compares the efficacy of patisiran and inotersen on neuropathy and qu...

journal_title：Expert opinion on pharmacotherapy

authors： Gorevic P,Franklin J,Chen J,Sajeev G,Wang JCH,Lin H

更新日期：2021-01-01 00:00:00

abstract：INTRODUCTION:Paget's disease of the bone is a common condition in some populations, affecting almost 10% of older adults in western Europe. Though frequently asymptomatic, it can sometimes result in severe disabilities. Timely intervention is now able to arrest disease progression in the majority of patients. AREAS CO...

journal_title：Expert opinion on pharmacotherapy

authors： Reid IR

更新日期：2012-04-01 00:00:00

abstract：INTRODUCTION:Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from stu...

journal_title：Expert opinion on pharmacotherapy

authors： Carrion AF,Gutierrez J,Martin P

更新日期：2014-04-01 00:00:00

abstract：INTRODUCTION:Chronic lymphocytic leukemia (CLL) often has an extended disease course. With a median age at diagnosis of 72 years, newer treatment options with less toxicity than standard nucleoside analogue-based regimens are needed. Historically, few therapy options are available once CLL has become refractory to nucl...

journal_title：Expert opinion on pharmacotherapy

authors： Chang JE,Kahl BS

更新日期：2012-07-01 00:00:00

abstract：INTRODUCTION:For more than two decades, lowering levels of low-density lipoprotein cholesterol has formed the cornerstone of management of patients with atherosclerotic cardiovascular disease. The substantial residual risk of clinical events in patients treated with statin therapy highlights the need to develop more ef...

journal_title：Expert opinion on pharmacotherapy

authors： Nicholls SJ,Pisaniello AD,Kataoka Y,Puri R

更新日期：2014-06-01 00:00:00

abstract：INTRODUCTION:Prostate cancer being the second leading cause of death in men in Western countries remains a major challenge in healthcare. Several novel agents targeting signaling pathways in prostate cancer have recently been approved by the US Food and Drug Administration (FDA) but there is still an unmet need for new...

journal_title：Expert opinion on pharmacotherapy

authors： Deshmukh RR,Schmitt SM,Hwang C,Dou QP

更新日期：2014-01-01 00:00:00

abstract：INTRODUCTION:Clostridium difficile has become the most important healthcare-associated infection worldwide within the past decade. This is in part due to the emergence of a highly virulent epidemic strain of C. difficile as well as the relative ineffectiveness of current therapies at producing a sustained response. Fid...

journal_title：Expert opinion on pharmacotherapy

authors： Hostler CJ,Chen LF

更新日期：2013-08-01 00:00:00

abstract：:The adrenal steroidal hormone dehydroepiandrosterone (DHEA) has been studied as a potential pharmacological agent in the treatment of the autoimmune disease systemic lupus erythematosus (SLE). Both the endocrine effects (the ability to be converted peripherally to androgenic and oestrogenic sex steroids) and the immun...

journal_title：Expert opinion on pharmacotherapy

authors： van Vollenhoven RF

更新日期：2002-01-01 00:00:00

abstract：:Pancreatic cancer has one of the worst prognosis of any malignant disease. Systemic therapy is often administered because the disease is usually detected at advanced stages. Gemcitabine (Gemzar trade mark, Eli Lilly & Co.) has proven activity in the treatment of pancreatic cancer. Gemcitabine 1000 mg/m(2) was given on...

journal_title：Expert opinion on pharmacotherapy

authors： Karasek P,Skacel T,Kocakova I,Bednarik O,Petruzelka L,Melichar B,Bustova I,Spurny V,Trason T

更新日期：2003-04-01 00:00:00

abstract：:Pharmacological relapse prevention in alcoholism is a rather new clinical field with few drugs being available. Acamprosate, acting predominantly via glutamatergic pathways, and the opioid receptor antagonist naltrexone, were both shown to be efficient in improving rates for continuous abstinence, and not relapsing to...

journal_title：Expert opinion on pharmacotherapy

authors： Soyka M,Roesner S

更新日期：2006-12-01 00:00:00

abstract：INTRODUCTION:Asthma is the most common chronic disease in childhood, affecting approximately 10% of all children, and is the leading cause of hospitalization in developed countries. In this paper we aimed to review the evidence on chemical pharmacotherapy for long-term treatment of pediatric asthma, according to the la...

journal_title：Expert opinion on pharmacotherapy

authors： Vitale C,Maglio A,Pelaia C,Vatrella A

更新日期：2017-05-01 00:00:00

abstract：INTRODUCTION:Anaerobes are the most predominant components of normal human skin and mucous membrane bacterial flora and are, therefore, a common cause of endogenous bacterial infections. Because of their fastidious nature, they are difficult to isolate from infectious sites and are often overlooked. Anaerobic infection...

journal_title：Expert opinion on pharmacotherapy

authors： Brook I

更新日期：2011-08-01 00:00:00